Nuevocor

Pioneering Novel Genetic Medicines for Previously Untreatable Genetic Cardiomyopathies

A leader in innovative, pathway-specific genetic medicines: Genetic cardiomyopathies, caused by mutations in over 30 genes linked to cardiac force transmission, represent a major unmet medical need, particularly since most mutations are inherited in an autosomal dominant pattern, making traditional gene replacement therapies unfeasible. Nuevocor’s mechanobiology PrOSIA platform enables the development of targeted genetic medicines by identifying shared biomechanical pathways in genetic cardiomyopathies. This approach surpasses traditional gene replacement therapies, offering a comprehensive treatment strategy.
Targeting the Root Cause of Lamin-Related Dilated Cardiomyopathy: There are no effective treatments beyond heart transplant for Lamin-related dilated cardiomyopathy (DCM). Nuevocor’s lead program, NVC-001, targets the biomechanical root cause of this aggressive disease. Data presented at ESGCT and AHA demonstrated promising therapeutic benefits and a strong safety profile in preclinical models, showing the potential for NVC-001.
Key Events in 2025: IND submission and initiation of clinical trials for NVC-001; Potential advancement of other pipeline programs